StemCells gets FDA nod for dry AMD trial using neural stem cells
This article was originally published in Scrip
Executive Summary
Cell therapy specialist StemCells has received authorisation from the US FDA to start a Phase I/II trial of its purified human neural stem cells (HuCNS-SC) for dry age-related macular degeneration, or dry AMD.